ICAM1 and melanoma: To evaluate the efficacy of ADCs with different MoAs for melanoma, we evaluated two in‐house ICAM1‐ADCs (namely I1‐MMAE and I1‐DXd) previously developed by us [10] via conjugating monoclonal ICAM1 antibodies with two clinically proven linker and payload combinations: GGFG‐DXd and MC‐Vc‐Pab‐MMAE (Figure 1E).